This multicenter retrospective cohort study included 53,607 patients with CKD stages 3–4. The primary exposure was the baseline TyG index, compared across quartiles with the second quartile (Q2) as the reference. The median follow-up duration was 31.18 months. The primary outcome was renal function progression, which occurred in 19,619 (36.6%) patients.
Regarding the main results, each 1-unit increase in the continuous TyG index was associated with a 10% higher risk of renal function progression (Hazard Ratio 1.10; 95% CI 1.07–1.12). When analyzed by quartiles, the highest quartile (Q4) demonstrated a significantly increased risk compared to Q2 (Hazard Ratio 1.17; 95% CI 1.12–1.22). Additionally, the association between the TyG index and renal function progression was non-linear and U-shaped, with the lowest risk (nadir) observed at a TyG index of approximately 8.6–8.8.
Safety and tolerability data were not reported, as were specific adverse events or discontinuations. The study noted that results were robust in sensitivity analyses, including a competing-risk model. However, because this was a retrospective cohort study, the TyG index is described as an independent predictor rather than a causal agent. No funding conflicts were reported.
The TyG index may serve as a valuable tool for early risk stratification in patients with CKD stages 3–4. Clinicians should interpret these associations cautiously, recognizing the limitations inherent to observational research.
View Original Abstract ↓
BackgroundThe progression of chronic kidney disease (CKD) is a major public health issue. Insulin resistance (IR) is a key mechanism, but simple biomarkers to predict progression in patients with established CKD stages 3–4 are needed. The Triglyceride-glucose (TyG) index is a reliable surrogate for IR. We aimed to investigate the longitudinal association between the baseline TyG index and the risk of renal function progression in patients with CKD stages 3–4.MethodsThis multicenter retrospective cohort study included 53,607 patients with CKD stages 3–4 from the China Renal Data System (CRDS) between 2005 and 2022. The baseline TyG index was calculated, and participants were divided into quartiles. The primary outcome was renal function progression. We used multivariate Cox proportional hazards models, restricted cubic splines (RCS), subgroup analyses, and competing-risk models to assess the association.ResultsDuring a median follow-up of 31.18 months, 19,619 (36.6%) patients experienced renal function progression. After full multivariate adjustment, each 1-unit increase in the continuous TyG index was associated with a 10% higher risk of renal function progression (Hazard Ratio [HR] 1.10, 95% CI 1.07–1.12). Compared to the second quartile (Q2, reference), the highest quartile (Q4) had a significantly increased risk (HR 1.17, 95% CI 1.12–1.22). The RCS analysis revealed a non-linear, U-shaped association between the TyG index and renal function progression, with the lowest risk (nadir) at a TyG index of approximately 8.6–8.8. This U-shaped association was consistent across subgroup analyses and robust in sensitivity analyses, including a competing-risk model treating all-cause death as the competing event.ConclusionThe TyG index is an independent predictor of renal function progression in patients with CKD stages 3–4, demonstrating a U-shaped relationship. As an inexpensive and readily available marker, the TyG index may serve as a valuable tool for early risk stratification in this high-risk population.